Press Releases

1,000 participants enrolled across two studies, and six sites Studies will evaluate clinical effectiveness beyond 6 months, impact on medication use and healthcare utilization SAN FRANCISCO --(BUSINESS WIRE)--Sep. 28, 2023-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing

Obtained FDA Authorization for AspyreRx TM to treat adults with type 2 diabetes Established price and launch metrics in preparation for expected launch in Q4 Completed financing transactions totaling $12.5 million in net proceeds Company to host conference call and webcast today at 4:30pm ET SAN

SAN FRANCISCO --(BUSINESS WIRE)--Aug. 2, 2023-- Better Therapeutics, Inc . (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its second quarter 2023 financial results after the market closes on Wednesday,

SAN FRANCISCO --(BUSINESS WIRE)--Jul. 25, 2023-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing software to treat cardiometabolic diseases, today announced that it issued 2,023,583 shares of its common stock under its At-The-Market program at an average price per share of $1.19 .

First prescription digital behavioral therapeutic device delivering novel form of cognitive behavioral therapy via smartphone In a randomized controlled trial AspyreRx demonstrated clinically meaningful and statistically significant durable reductions in A1c Company to host conference call and

Naim Alkhouri , MD, FAASLD, to Present Findings from Non-alcohol Related Fatty Liver Disease Feasibility Study SAN FRANCISCO --(BUSINESS WIRE)--Jun. 16, 2023-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated,

On track for an FDA decision mid-year Announced restructuring to extend cash runway Completed private placement financing Company to host conference call and webcast today at 8:30 a.m. ET SAN FRANCISCO --(BUSINESS WIRE)--May 11, 2023-- Better Therapeutics, Inc.

SAN FRANCISCO --(BUSINESS WIRE)--May 4, 2023-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today

SAN FRANCISCO --(BUSINESS WIRE)--Apr. 6, 2023-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases,

Advanced preparations for potential commercial launch of BT-001 in U.S. in mid-2023 Reported positive topline results   from exploratory trial for fatty liver disease Announced restructuring and other cost saving actions to extend financial runway Company to host conference call and webcast today